All In Biotech

Drug Trial Radar · NCT07613450

A Phase III Study of SYHA1813 for Recurrent or Progressive High-Grade Meningiomas

SYHA1813 vs Investigators' Choice Treatment in Patients With Recurrent or Progressive High-Grade Meningiomas: A Randomized, Controlled, Multicenter, Phase III Study

Last checked: Nov 20, 2026Latest source record: May 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 136 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

136

Planned (sponsor's estimate)

Start

May 20, 2026

Primary completion

Jul 31, 2029

Study completion Oct 15, 2029

Sponsor

Sponsor type
Industry
First posted
May 29, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, controlled, open-label, multicenter, Phase III clinical study designed to compare the efficacy and safety of SYHA1813 versus treatment of investigators' choice in patients with recurrent or progressive high-grade meningioma not amenable to local therapy.

Conditions

  • High Grade Meningioma

Interventions

  • SYHA1813Drug

    SYHA1813 20mg QD

  • Investigator's Choice TreatmentDrug

    Investigator's Choice Treatment:bevacizumab, temozolomide or hydroxyurea

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS) as Assessed by RANO Criteria and Evaluated by BIRCTime frame: Up to approximately 4 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.